[PRESS RELEASE] – LONDON, May 12, 2025 – Curaleaf International, part of Curaleaf Holdings Inc., in collaboration with Jupiter Research LLC, a subsidiary of TILT Holdings Inc., has secured regulatory approval for the first handheld liquid inhalation device designed for precise medical cannabis administration. This EU medical device certification (Regulation (EU) 2017/745) paves the way for improved patient options and a new era of innovation in medical cannabis delivery.
The liquid inhalation device is now certified as a Class IIa medical device, meeting rigorous European regulatory standards. The device includes a magnetic snap-in cartridge and a rechargeable power supply, engineered to provide a consistent and controlled cannabinoid delivery. A recognized EU Notified Body assessed and approved a comprehensive technical file and full EU Declaration of Conformity, validating the device’s quality, safety and clinical robustness.
EU certification supports deployment in multiple global markets and, once commercialized, will enable health care professionals to recommend the device offered by Curaleaf International in European countries, the U.K., Canada and regions across Australasia.
"Achieving EU medical certification is more than a regulatory milestone—it's a signal that medical cannabis innovation is moving into the mainstream of global health care,” Curaleaf Chairman and CEO Boris Jordan said. “We're proud to offer a device that meets the highest standards of safety and quality, and we look forward to supporting patients and health care providers across Europe and beyond with a new, accurate and discrete option for treatment."
TILT CEO Tim Conder said, “Partnering with Curaleaf International on this project has been a natural extension of our long-standing partnership in the U.S. By delivering industry-leading, user-friendly solutions, our collaboration exemplifies how technology can revolutionize health care. Achieving EU medical certification on IP developed by our subsidiary Jupiter Research validates the robustness of our engineering and R&D functions and sets a new benchmark for the industry.”
This development reinforces Curaleaf International’s role at the forefront of advancing access to legal, high-quality cannabis treatments across Europe and other international markets.
